LOS ANGELES, CA--(Marketwired - Oct 7, 2013) - MAX BioPharma (www.maxbiopharma.com) announced today that the company has exclusively licensed intellectual property involving proprietary small molecule oxysterols from UCLA and Johns Hopkins University. In related news, MAX BioPharma has received its first SBIR grant from the National Institute of Health to pursue the development of a new class of drugs based on the oxysterol technology for stimulating bone formation in patients with osteoporosis. The company will be making a presentation at the BIO Investor Forum on Tuesday October 8, 2013, in San Francisco.

MAX BioPharma's first lead candidate molecule for stimulating bone formation to treat bone fractures, induce bone fusion in spine surgeries, and regenerate maxillofacial bone defects has shown impressive results in a number of preclinical animal models. 

About MAX BioPharma
MAX BioPharma Inc. is a start up biopharmaceutical company engaged in discovery and development of novel small molecules to target human disorders including non-healing bone fractures, osteoporosis, and cancer. The company will be a leader in the new fields of "lipidomics" and "oxysterol therapeutics" by leveraging a growing portfolio of IP that will lead to treatments for numerous indications. MAX BioPharma's first success based on small molecule lipids has contributed to the discovery of novel osteogenic oxysterol compounds that target multipotent mesenchymal cells, including mesenchymal stem cells, to induce the formation bone forming osteoblasts and bone in vitro and in vivo. The company is developing this technology into the next generation of therapeutic agents for stimulation of bone formation locally and systemically in indications such as spinal fusion, non-union fractures, and osteoporosis. MAX BioPharma is also pursuing the development of small molecule oxysterols that function as Hedgehog pathway antagonists in tumor microenvironment and will be more effective than currently known Hedgehog pathway antagonists in treating a variety of Hedgehog pathway-related cancers, including pancreatic cancer and multiple myeloma. For more information please visit us at www.maxbiopharma.com

Contact Information:

Media Contact:
Zachary Cotner
Director of Corporate Finance